An experimental cancer blood test designed to pinpoint cancer cells is being developed for medical use. Earlier detection could possibly be one of the biggest benefits provided by the brand new cancer blood test. Testing a patient's blood using the brand new technique might result in more effective treatment and help determine if the cancer has been defeated. Post resource - New cancer blood test could revolutionize diagnosis and treatment by MoneyBlogNewz.
Cancer treatment breakthrough ahead of us
The Harvard University and Johnson & Johnson medical researchers are coming up with a new cancer blood test. There would no longer be biopsies, mammograms or even colonoscopies. Better outcomes would be produced with a teaspoon of blood. The cancer blood test is intended to detect circulating tumor cells (CTCs), cancer cells that separate from a tumor and migrate to other organs via the bloodstream. The CTCs are in the body spreading cancer. This is the only way expected that it can spread too. Based on the number of CTCs detected, the test might reveal how well-off the patient is.
Ways to use the cancer blood examination
The cancer blood test involves a microchip the size of a business card covered with 78,000 tiny posts. Cancer cells are drawn from the blood sample because of antibodies on the posts. Nothing happens to the posts when all the cells are healthy blood cells. Any cells that are cancerous will stick to them though. The cancer cells will glow if they are stuck to the posts because of a dye added so they may be counted. The brand new cancer blood examination is extremely sensitive to cancerous cells also. In fact, out of millions of healthy blood cells, just one cancerous cell will be detected. In addition to counting the cancer cells, it's possible that a gene analysis of the cell could provide data leading to the most effective cancer treatments.
<p><strong>May be utilized in three to five years
Researchers said patients with prostate, bladder, colon, kidney and lung cancer could benefit most from the new cancer blood examination. Johnson & Johnson has invested $30 million within the process, which unfolds much like the development of new drugs that are submitted to the FDA for approval. The procedure might be available for clinical use in 3 to five years.